Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Journal: American journal of hematology
Published: September 10, 2024
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Journal: JCO oncology practice
Published: April 16, 2024
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 12, 2023
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.
Journal: Blood and lymphatic cancer : targets and therapy
Published: June 09, 2020
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2019
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Journal: American journal of hematology
Published: August 14, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Journal: Haematologica
Published: March 17, 2018
A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies.
Journal: Case reports in hematology
Published: March 06, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026